Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of HuidaGene Therapeutics.

    Client Virtual Booth

    HUIDAGENE THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    HuidaGene Therapeutics
    China Flag
    Country
    Country
    China
    Address
    Address
    2nd Floor, Unit 3, Building 5 No. 160 Basheng Road, Pudong New Area Shanghai
    Telephone
    Telephone
    021-80118181
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.huidagene.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/huidagene/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Huidagene Therapeutics Announces First Patient Dosed in Multinational Phase 1/2 Trial of HG004 for Inherited Blindness

    Details:

    HG004 is an investigational gene replacement therapy product. It uses the recombinant AAV9 vector to deliver a functional human RPE65 gene to the retina and to restore, treat, and prevent blindness of children and adults with RPE65-Inherited Retinal Diseases.


    Lead Product(s): HG004

    Therapeutic Area: Rare Diseases and Disorders Product Name: HG004

    Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 01, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Huidagene Therapeutics Receives FDA Rare Pediatric Disease Designation for HG004 to Treat Inherited Blindness

    Details:

    HG004 is a one-time, direct-to-RPE treatment of inherited retinal disease caused by mutations in the RPE65 gene and was previously granted orphan drug designation for RPE65-IRD.


    Lead Product(s): HG004

    Therapeutic Area: Ophthalmology Product Name: HG004

    Highest Development Status: Phase IProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 07, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Huida Genomics HG004 IND Was Approved By NMPA, And China's First International Multi-Regional, Multi-Center Gene Therapy Drug Clinical Trial with The Sa...

    Details:

    HG004 injection is a new ophthalmic gene therapy drug designed to treat RPE65 gene mutation-related retinopathy. It has successfully obtained the IND approval from the US FDA


    Lead Product(s): HG004

    Therapeutic Area: Ophthalmology Product Name: HG004

    Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 18, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    HuidaGene Receives Orphan Drug Designation for Gene Therapy of Blindness

    Details:

    HG004 is a gene replacement therapy drug which uses the recombinant non-adeno-associated virus serotype 2 vector to deliver a functional human RPE65 gene to the retina to restore, treat, and prevent blindness of children and adults with RPE65 mutation-associated IRDs.


    Lead Product(s): HG004

    Therapeutic Area: Ophthalmology Product Name: HG004

    Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 03, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Huida Gene's First Gene Therapy Drug Approved By IND in the United States, And International Multi-Center Clinical Trials Will Be Carried Out

    Details:

    HG004 is an ophthalmic injection intended for the treatment of RPE65 gene mutation-related retinopathy. Based on direct preclinical comparative studies of HG004 and AAV2 in retinal function, HG004 is at least 10 times more efficient at transducing retinal pigment epithelium.


    Lead Product(s): HG004

    Therapeutic Area: Ophthalmology Product Name: HG004

    Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 27, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search